logo
Estimating The Fair Value Of Life360, Inc. (ASX:360)

Estimating The Fair Value Of Life360, Inc. (ASX:360)

Yahoo5 hours ago

Life360's estimated fair value is AU$30.82 based on 2 Stage Free Cash Flow to Equity
With AU$33.25 share price, Life360 appears to be trading close to its estimated fair value
Our fair value estimate is 4.8% higher than Life360's analyst price target of US$29.42
How far off is Life360, Inc. (ASX:360) from its intrinsic value? Using the most recent financial data, we'll take a look at whether the stock is fairly priced by taking the expected future cash flows and discounting them to their present value. One way to achieve this is by employing the Discounted Cash Flow (DCF) model. It may sound complicated, but actually it is quite simple!
We would caution that there are many ways of valuing a company and, like the DCF, each technique has advantages and disadvantages in certain scenarios. If you want to learn more about discounted cash flow, the rationale behind this calculation can be read in detail in the Simply Wall St analysis model.
This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.
We are going to use a two-stage DCF model, which, as the name states, takes into account two stages of growth. The first stage is generally a higher growth period which levels off heading towards the terminal value, captured in the second 'steady growth' period. In the first stage we need to estimate the cash flows to the business over the next ten years. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.
Generally we assume that a dollar today is more valuable than a dollar in the future, so we discount the value of these future cash flows to their estimated value in today's dollars:
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
Levered FCF ($, Millions)
US$58.8m
US$84.5m
US$143.6m
US$175.0m
US$216.0m
US$247.1m
US$274.2m
US$297.7m
US$318.1m
US$336.3m
Growth Rate Estimate Source
Analyst x3
Analyst x3
Analyst x3
Analyst x1
Analyst x1
Est @ 14.40%
Est @ 10.96%
Est @ 8.56%
Est @ 6.88%
Est @ 5.70%
Present Value ($, Millions) Discounted @ 7.9%
US$54.5
US$72.6
US$114
US$129
US$148
US$157
US$161
US$163
US$161
US$158
("Est" = FCF growth rate estimated by Simply Wall St)Present Value of 10-year Cash Flow (PVCF) = US$1.3b
After calculating the present value of future cash flows in the initial 10-year period, we need to calculate the Terminal Value, which accounts for all future cash flows beyond the first stage. The Gordon Growth formula is used to calculate Terminal Value at a future annual growth rate equal to the 5-year average of the 10-year government bond yield of 2.9%. We discount the terminal cash flows to today's value at a cost of equity of 7.9%.
Terminal Value (TV)= FCF2034 × (1 + g) ÷ (r – g) = US$336m× (1 + 2.9%) ÷ (7.9%– 2.9%) = US$7.1b
Present Value of Terminal Value (PVTV)= TV / (1 + r)10= US$7.1b÷ ( 1 + 7.9%)10= US$3.3b
The total value, or equity value, is then the sum of the present value of the future cash flows, which in this case is US$4.6b. To get the intrinsic value per share, we divide this by the total number of shares outstanding. Compared to the current share price of AU$33.3, the company appears around fair value at the time of writing. Remember though, that this is just an approximate valuation, and like any complex formula - garbage in, garbage out.
We would point out that the most important inputs to a discounted cash flow are the discount rate and of course the actual cash flows. Part of investing is coming up with your own evaluation of a company's future performance, so try the calculation yourself and check your own assumptions. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Life360 as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 7.9%, which is based on a levered beta of 1.133. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.
View our latest analysis for Life360
Strength
Currently debt free.
Weakness
No major weaknesses identified for 360.
Opportunity
Annual earnings are forecast to grow faster than the Australian market.
Good value based on P/S ratio compared to estimated Fair P/S ratio.
Threat
Revenue is forecast to grow slower than 20% per year.
Although the valuation of a company is important, it shouldn't be the only metric you look at when researching a company. The DCF model is not a perfect stock valuation tool. Preferably you'd apply different cases and assumptions and see how they would impact the company's valuation. For instance, if the terminal value growth rate is adjusted slightly, it can dramatically alter the overall result. For Life360, we've compiled three further elements you should further research:
Risks: Every company has them, and we've spotted 2 warning signs for Life360 you should know about.
Future Earnings: How does 360's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.
Other Solid Businesses: Low debt, high returns on equity and good past performance are fundamental to a strong business. Why not explore our interactive list of stocks with solid business fundamentals to see if there are other companies you may not have considered!
PS. Simply Wall St updates its DCF calculation for every Australian stock every day, so if you want to find the intrinsic value of any other stock just search here.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Alys Pharmaceuticals announces CTA submission for ALY-301, the first mast cell selective c-Kit inhibitor for treatment of Cold Urticaria
Alys Pharmaceuticals announces CTA submission for ALY-301, the first mast cell selective c-Kit inhibitor for treatment of Cold Urticaria

Yahoo

time29 minutes ago

  • Yahoo

Alys Pharmaceuticals announces CTA submission for ALY-301, the first mast cell selective c-Kit inhibitor for treatment of Cold Urticaria

ALY-301 is a first-in-class bispecific antibody targeting c-Kit and CD-203c with mast cell selectivity Designed to enable safe dosing in chronic conditions and deliver clinical proof-of concept in a Phase 1/1b study BOSTON and LAUSANNE, Switzerland, June 10, 2025 /PRNewswire/ -- Alys Pharmaceuticals, Inc. ("Alys"), an immune-dermatology focused company, today announces the submission of a Clinical Trial Application (CTA) to Germany's Paul-Ehrlich-Institut (PEI) to initiate a Phase 1/1b study of ALY-301 in healthy volunteers and patients suffering from Cold Urticaria, a subtype of Chronic Inducible Urticaria (CIndU). Cold Urticaria is a chronic skin disease where red, itchy wheals or hives appear after the skin is exposed to cold temperatures. It is a well-established clinical model for mast cell-mediated diseases in general, and chronic spontaneous urticaria in particular. Current and emerging solutions do not address the significant unmet medical needs experienced by patients. In conjunction with limited treatment options, the Urticaria market is projected to reach multiple billions within the next ten years. ALY-301 is the first mast cell-selective c-Kit inhibitor to enter the clinic. It is a cis-targeting bispecific antibody binding c-Kit and CD-203c, allowing selective targeting and depletion of mast cells over other c-Kit positive cells. This differentiated profile of ALY-301 is expected to offer a significantly improved safety profile over conventional c-Kit targeting agents and enable safe, chronic dosing in multiple mast-cell dependent diseases such as Chronic Urticaria. The trial will evaluate the safety and efficacy of ALY-301 at multiple sites across Germany. This CTA submission is the first clinical program to emerge from Alys' Granular platform, which is focused on the precise targeting of mast cell biology through advanced antibody engineering. Professor Brian Kim, Sol and Clara Kest Professor of Dermatology and Vice Chair of Research at Icahn School of Medicine at Mount Sinai and Head of Alys Pharmaceuticals Scientific Advisory Board, said: "ALY-301 offers a truly differentiated approach. It is the only c-Kit antibody designed to target activated mast cells while avoiding off-target effects. Unleashing the proven efficacy of c-Kit inhibition on mast cells, while sparing all other cell-types that have been associated with significant side effects, should result in a transformational drug profile for ALY-301 and could have a revolutionary impact on Chronic Urticaria and several other allergic indications." Professor Martin Metz, Professor of Dermatology at the Institute of Allergology at the Charité – Universitätsmedizin Berlin & Fraunhofer Institute for Translational Medicine and Pharmacology, Allergology and Immunology and Principal Investigator for ALY-301, commented: "The concept behind ALY-301, to enable safe and effective chronic dosing of a c-Kit agent through mast-cell selectivity, has been strongly supported across all non-clinical studies. It is very exciting to start the clinical journey today, especially since this first clinical trial will yield clinical outcomes from Urticaria patients." Thibaud Portal, Co-Founder and Chief Operating Officer of Alys Pharmaceuticals, added: "Recently, there has been intense attention to solving Urticaria and other allergic diseases, with keen interest in c-Kit targeting. Data have demonstrated the remarkable potency of the mode of action, but indiscriminate c-Kit targeting has been coupled with chronic safety challenges. ALY-301 is a first-in-class approach that combines the power of c-Kit inhibition with selectivity and safety. With its expected safety margin and broad applicability across multiple diseases, this marks another pivotal moment for Alys in our journey to bring innovative treatments to patients." This study marks the second major clinical milestone for Alys Pharmaceuticals. The Alys pipeline includes a diverse portfolio of assets targeting unmet needs in indications such as atopic dermatitis, chronic spontaneous urticaria, vitiligo, and systemic mastocytosis. The Company remains on track to deliver multiple clinical Proof-of-Concept (POC) readouts by 2027. About Alys PharmaceuticalsAlys Pharmaceuticals, Inc. ("Alys") is a Boston and Lausanne-based cutting edge pure-play immuno-dermatology company. Alys is backed by international investment firm Medicxi with $100M financing. Alys has a world class leadership team that brings together experts across dermatology and advanced scientific fields, including co-founders John Harris (UMass Chan Medical School), Brian Kim (Icahn School of Medicine at Mount Sinai), Lars French (LMU, Munich), Craig Mello (UMass Chan Medical School), Eric Deutsch (Gustave Roussy) and Mark Prausnitz (Georgia Institute of Technology). Alys is led by dermatology specialist, co-founder, and COO Thibaud Portal. Its pipeline includes programs targeting multiple dermatological indications, including atopic dermatitis, vitiligo, chronic urticaria, psoriasis and mastocytosis. The Company entered the clinic in Q1 2025 with the siRNA platform developed by its affiliate Aldena Therapeutics, which offers the potential for long-lasting treatments that could transform the dermatology treatment landscape and is now advancing its mastocyte-selective therapies developed by affiliate Granular Therapeutics. For further information, please visit View original content: SOURCE Alys Pharmaceuticals Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

AlbaCore Capital Brings Aboard Diarmuid Curran to Enhance European CLO Capabilities
AlbaCore Capital Brings Aboard Diarmuid Curran to Enhance European CLO Capabilities

Yahoo

time29 minutes ago

  • Yahoo

AlbaCore Capital Brings Aboard Diarmuid Curran to Enhance European CLO Capabilities

LONDON, June 10, 2025--(BUSINESS WIRE)--European credit specialist, AlbaCore Capital Group ("AlbaCore"), has announced the appointment of Diarmuid Curran as Managing Director and Portfolio Manager. Diarmuid will focus on AlbaCore's leading European CLO platform – both new issuance and existing CLO fund management, reporting to Deborah Cohen Malka, Partner and Portfolio Manager, who leads the CLO business. "I'm pleased to welcome Diarmuid to the team at AlbaCore," said Deborah Cohen Malka. "His background and experience will strengthen our capabilities as we continue to take advantage of the pipeline of opportunities in Europe on behalf of our investor base." Diarmuid joins AlbaCore from Napier Park Global Capital, where he served as a Portfolio Manager. In that capacity, he was responsible for managing a portfolio of European loans and High Yield bonds held in CLOs as well as credit selection and underwriting as a member of the Investment Committee. "I've been impressed from afar by AlbaCore's reputation in the European market," said Diarmuid Curran. "I look forward to working with Deborah and the team to build upon their well-established European CLO business." In March of this year, AlbaCore successfully priced AlbaCore Euro CLO VII - it's 7th CLO – bringing the total value of CLO platform assets under management to c. €2.9 billion. The CLO platform incorporates negative ESG screening criteria in combination with AlbaCore's fundamental research and risk focused ESG considerations, including restrictions on the industries in which the CLO can invest. About AlbaCore Capital Group AlbaCore Capital Group is one of Europe's leading alternative credit specialists, investing in private capital solutions, direct lending, opportunistic and dislocated credit, CLOs, and structured products. Founded in 2016, AlbaCore is part of the First Sentier Investors Group. AlbaCore's investment philosophy is focused on capital preservation and generating attractive risk adjusted returns through the cycle for its investors. AlbaCore manages US $10.0 billion in AuM3 as of 31 March 2025 on behalf of global pension funds, sovereign wealth funds, endowments, insurance companies, family offices and high net worths around the world. For more information, visit View source version on Contacts Media Contacts: Lansons (London) Rakin Sayed +447581036067 rakins@ Lansons (New York) James Schiavone 917-238-9614 jamess@ Se produjo un error al recuperar la información Inicia sesión para acceder a tu portafolio Se produjo un error al recuperar la información Se produjo un error al recuperar la información Se produjo un error al recuperar la información Se produjo un error al recuperar la información

AlbaCore Capital Brings Aboard Diarmuid Curran to Enhance European CLO Capabilities
AlbaCore Capital Brings Aboard Diarmuid Curran to Enhance European CLO Capabilities

Business Wire

time33 minutes ago

  • Business Wire

AlbaCore Capital Brings Aboard Diarmuid Curran to Enhance European CLO Capabilities

LONDON--(BUSINESS WIRE)--European credit specialist, AlbaCore Capital Group ('AlbaCore'), has announced the appointment of Diarmuid Curran as Managing Director and Portfolio Manager. Diarmuid Curran has joined AlbaCore as Managing Director and Portfolio Manager, bringing a wealth of experience in European credit markets to further strengthen the team and support the continued growth of the firm's European CLO platform. Diarmuid will focus on AlbaCore's leading European CLO platform – both new issuance and existing CLO fund management, reporting to Deborah Cohen Malka, Partner and Portfolio Manager, who leads the CLO business. 'I'm pleased to welcome Diarmuid to the team at AlbaCore,' said Deborah Cohen Malka. 'His background and experience will strengthen our capabilities as we continue to take advantage of the pipeline of opportunities in Europe on behalf of our investor base.' Diarmuid joins AlbaCore from Napier Park Global Capital, where he served as a Portfolio Manager. In that capacity, he was responsible for managing a portfolio of European loans and High Yield bonds held in CLOs as well as credit selection and underwriting as a member of the Investment Committee. 'I've been impressed from afar by AlbaCore's reputation in the European market,' said Diarmuid Curran. 'I look forward to working with Deborah and the team to build upon their well-established European CLO business.' In March of this year, AlbaCore successfully priced AlbaCore Euro CLO VII - it's 7 th CLO – bringing the total value of CLO platform assets under management to c. €2.9 billion. The CLO platform incorporates negative ESG screening criteria in combination with AlbaCore's fundamental research and risk focused ESG considerations, including restrictions on the industries in which the CLO can invest. About AlbaCore Capital Group AlbaCore Capital Group is one of Europe's leading alternative credit specialists, investing in private capital solutions, direct lending, opportunistic and dislocated credit, CLOs, and structured products. Founded in 2016, AlbaCore is part of the First Sentier Investors Group. AlbaCore's investment philosophy is focused on capital preservation and generating attractive risk adjusted returns through the cycle for its investors. AlbaCore manages US $10.0 billion in AuM3 as of 31 March 2025 on behalf of global pension funds, sovereign wealth funds, endowments, insurance companies, family offices and high net worths around the world.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store